BioMed Research International

BioMed Research International / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 1648715 | https://doi.org/10.1155/2017/1648715

Xinyi Liu, Yongliang Wang, Shuhong Zhao, Xinyun Li, "Fibroblast Growth Factor 21 Promotes C2C12 Cells Myogenic Differentiation by Enhancing Cell Cycle Exit", BioMed Research International, vol. 2017, Article ID 1648715, 9 pages, 2017. https://doi.org/10.1155/2017/1648715

Fibroblast Growth Factor 21 Promotes C2C12 Cells Myogenic Differentiation by Enhancing Cell Cycle Exit

Academic Editor: Pere Domingo
Received12 May 2017
Revised30 Jul 2017
Accepted06 Aug 2017
Published04 Oct 2017

Abstract

Fibroblast growth factor 21 (FGF21), a secretion protein, functions as a pivotal regulator of energy metabolism and is being considered as a therapeutic candidate in metabolic syndromes. However, the roles of FGF21 in myogenic differentiation and cell cycle remain obscure. In this study, we investigated the function of FGF21 in myogenesis and cell cycle exit using C2C12 cell line. Our data showed that the expression of myogenic genes as well as cell cycle exit genes was increased after FGF21 overexpression, and FGF21 overexpression induces cell cycle arrest. Moreover, cell cycle genes were decreased in FGF21 overexpression cells while they were increased in FGF21 knockdown cells. Further, FGF21/P53/p21/Cyclin-CDK has been suggested as the key pathway for cell cycle exit mediated by FGF21 in C2C12 cells. Also, we deduce that FGF21 promotes the initiation of myogenic differentiation mainly through enhancing cell cycle exit of C2C12 cells. Taken together, our results demonstrated that FGF21 promotes cell cycle exit and enhances myogenic differentiation of C2C12 cells. This study provided new evidence that FGF21 promotes myogenic differentiation, which could be useful for better understanding the roles of FGF21 in myogenesis.

1. Introduction

Fibroblast growth factor 21 (FGF21), a member of the FGF family, was initially identified by Nobuyuki Itoh’s group [1], and its bioactivity was first discovered as a potential regulator of glucose uptake in mouse and human adipocytes [2]. Signaling pathway studies indicated that FGF21 could bind fibroblast growth factor receptor (FGFR) 1/2 and coreceptor -Klotho after being secreted from tissues [3, 4]. FGFR1 or -Klotho knockout mice are refractory to the effects mediated by FGF21 [57]. FGF21 can be induced in multiple tissues including liver, pancreas, adipose tissue, and skeletal muscle [812]. However, the major organ of FGF21 releasing varies in response to different stimulation. In rodents, the liver tissue is the major source of FGF21 in the conditions of fasting and ketogenesis [13, 14], while under cold exposure, brown adipose tissue becomes an important organ of FGF21 generation [15]. In addition, circulating FGF21 was also increased in several pathological statuses including obesity, diabetes, and other metabolic syndromes in rodents and humans [1618]. As reported, in obesity and diabetes, markedly elevated circulating FGF21 level has led to an FGF21-resistant state. Moreover, the response to exogenous FGF21 is impaired and the expression of FGF21 receptors is reduced [1921].

It has been demonstrated that FGF21 functions as a regulator of glucose and lipid metabolism as well as energy homeostasis. Some studies reported that increasing of FGF21 could ameliorate obesity and diabetes through enhancing glucose uptake, suppressing adipogenesis, or increasing lipolysis both in vitro and in vivo [2224]. Currently, FGF21 has been treated as a therapeutic target of metabolism disorders [25]. Furthermore, FGF21 can prevent isoproterenol-induced cardiac hypertrophy and diabetes-induced cardiac apoptosis through MAPK pathway in mice [26, 27]. FGF21 also plays important roles in myogenesis. In the first few years, skeletal muscle was not considered as a source of FGF21. Later, one study carried out on mice demonstrated that skeletal muscle can also act as a source of FGF21 and it can be regulated via PI3K/Akt1 pathway [12]. Moreover, some studies reported that FGF21 could be induced in skeletal muscle by hyperinsulinemia and exercise in human beings [2831]. FGF21 is associated with myogenic differentiation and regulated by myogenic factor MyoD; also, FGF21 is involved in myofiber type transformation [32, 33].

FGF21 is currently considered as a myokine and adipokine, which mediates the cross talk between skeletal muscle and adipose tissue in energy metabolism [34, 35]. In human skeletal muscle, FGF21 can directly increase glucose uptake [17]. It has been reported that the improvement of glucose clearance by FGF21 treatment was lost in the absence of UCP1 [36]. Furthermore, a study revealed that the ectopic expression of UCP1 in skeletal muscle upregulates FGF21 level in both skeletal muscle and circulation system, and increased FGF21 promotes browning of white adipose tissue [35]. In addition, FGF21 enhances mitochondrial function via PGC1α pathway in response to skeletal muscle mitochondrial respiratory chain deficiency in humans. Further, lack of FGF21 impairs the upregulation of PGC1α induced by fasting in mice [3739].

Previous studies confirmed that FGF21 plays important roles in myogenesis. In order to further investigate the mechanisms of FGF21 in myogenesis, we first detected the expression of FGF21, β-Klotho, MyoD, Myogenin, Myf5, and cell cycle related genes during myogenic differentiation of C2C12 cells. Then, the function and mechanisms of FGF21 in myogenesis and cell cycle progression were studied in vitro. Our study offered useful information for better understanding the roles of FGF21 in myogenesis.

2. Materials and Methods

2.1. Cell Culture and Differentiation

C2C12 mouse myoblasts were cultured in DMEM containing 10% FBS and maintained in a humidified incubator with 5% CO2 at 37°C. For myogenic differentiation, when confluence was reached, C2C12 cells were shifted into a differentiation medium supplemented DMEM with 2% FBS.

2.2. FGF21 Overexpression and Stable Overexpression Cells Selection

The full length of mouse FGF21 CDS sequence was amplified using gene-specific primers and cloned into pCDNA3.1 expression vector. After being verified by sequencing, the expression vector containing full length of mouse FGF21 CDS was named pCDNA3.1-FGF21. For FGF21 overexpression, C2C12 cells were seeded on a 6-well plate the day before; when cells reached 60–70% confluence, transfection of FGF21 overexpression vector (pCDNA3.1-FGF21) and control vector (pCDNA3.1) was carried out using Lipofectamine 2000 following the manufacturer’s instructions. In terms of establishment of FGF21 stably expressed cells, 48 hours after transfection, cells were selected by adding G418 to the culture medium. After at least 2 weeks of selection, FGF21 stably expressed cells were obtained.

2.3. RNA Interference

In order to knock down FGF21 gene, double-stranded small interference RNAs targeting FGF21 and scrambled sequence as control were obtained from GenePharma (Shanghai, China). C2C12 cells were transfected with siRNAs, and after 48 hours, cells were harvested for analysis.

2.4. Enzyme-Linked Immunosorbent Assay (ELISA)

Cell medium was collected at 0 and 2 days of myogenic differentiation individually and centrifuged at 3000 rpm for 5 minutes to harvest the cell supernatant. The level of FGF21 protein in the cell supernatant was detected using the mouse FGF21 ELISA kit (Hangzhou, China) according to the manufacturer’s instructions.

2.5. RNA Extraction, Reverse Transcription, and Quantitative PCR

Total RNA was isolated with TRIzol reagent (Invitrogen, USA) following the manufacturer’s instructions. The purity and concentration of the RNA samples were measured using NanoDrop 2000. After that, 1 microgram of each RNA sample was used to synthesize cDNA using PrimeScript 1st strand cDNA synthesis kit (Takara, Japan) following the manufacturer’s instructions. Real-time quantitative PCR was performed using QuantiFast SYBR Green PCR kit (Qiagen, USA) on a CFX96 qPCR System (Bio-Rad, USA). And mRNA levels were quantified relatively to the expression of GAPDH by employing value, and Student’s -test was used for statistical comparison. Primers for quantitative PCR are listed in the Supplement Table (in the Supplementary Material available online at https://doi.org/10.1155/2017/1648715).

2.6. Western Blot

Total protein was extracted using RIPA buffer and the concentration was determined by Pierce BCA protein assay kit (Thermo, USA). Equal amounts of proteins were loaded and separated by SDS-PAGE gel before being blotted onto PVDF membranes (Millipore, USA). After the transfer, the membranes were blocked by 5% BSA for 1 hour at room temperature and then incubated with a primary antibody at 4°C overnight. The antibodies used in this study include FGF21 (1 : 1000, Abcam, USA), MyoD (1 : 500, Santa Cruz, USA), MyoG (1 : 500, Santa Cruz, USA), MEF2c (1 : 500, Santa Cruz, USA), MHC (1 : 500, Santa Cruz, USA), CDK4 (1 : 1000, CST, USA), P21 (1 : 1000, R&D, USA), P53 (CST) Cyclin D1 (1 : 1000, R&D, USA), Cyclin D3 (1 : 1000, R&D, USA), and tubulin (1 : 1000, Abcam, USA), which were diluted with 5% BSA.

2.7. Immunofluorescence

For immunofluorescence analysis, after differentiation, cells were washed with cold PBS and then fixed in 4% paraformaldehyde for 40 minutes and permeabilized in 0.2% Triton X-100-PBS for 10 minutes. After washing three times (10 minutes each) in PBS, cells were blocked with 5% BSA for 2 hours at room temperature and then incubated with anti-MHC primary antibody (Santa Cruz) at 4°C overnight. Alexa Fluor 488-labeled goat anti-mice IgG (Beyotime, China) was used as secondary antibody, and nuclei were stained with DAPI. The fluorescence images were gathered using Axio Observer microscope (Zeiss, USA) and Image Pro Plus.

2.8. Cell Cycle Analysis

The FGF21 gene stable overexpression cells were seeded on a 6-well plate and cultured for 24 hours; cells were then washed with PBS and fixed in 70% ethanol at 4°C overnight. Subsequently, cells were resuspended with PBS and incubated with propidium iodide (PI) in the presence of RNase A at 37°C for 30 minutes, and then DNA content was analyzed using a flow cytometer (Beckman, USA).

3. Results

3.1. FGF21 Showed Similar Expression Pattern to Myogenic Marker Genes and Cell Cycle Exit Genes during Myogenic Differentiation

First, we assessed the gene expression patterns at the early stage of myogenic differentiation of C2C12 cells. As is shown, the expression of FGF21 and its coreceptor -Klotho as well as myogenic factors MyoD, MyoG, and Myf5 was increased at the transcriptional level in response to early myogenic differentiation (Figure 1(a)). Further, the mRNA levels of cell cycle exit genes P16, P18, P19, and P21 were upregulated during early myogenic differentiation (Figure 1(b)). Moreover, western blot results confirmed that FGF21, MEF2c, MyoG, and P21 were upregulated during the early stage of myogenic differentiation, while Cyclin D3 was downregulated (Figure 1(c)). In addition, the ELISA results demonstrated that the FGF21 protein level in the cell medium is also increased in response to myogenic differentiation (Figure 1(d)).

3.2. Overexpression of FGF21 Promotes Myogenic Differentiation and Inhibits Proliferation of C2C12 Cells

In order to elucidate the functions of FGF21 in myogenic differentiation, FGF21 stable overexpression C2C12 cells were established. Q-PCR results showed that the mRNA levels of MyoG, MyoD, and Myf5 were significantly upregulated in FGF21 overexpression cells (). The expression of -Klotho has a tendency of upregulation in FGF21 overexpression cells but did not reach a statistically significant level (Figure 2(a)). Also, immunofluorescence results showed that MHC signal at 4 days of differentiation was obviously stronger in FGF21 overexpression C2C12 cells (Figure 2(b)). In addition, western blot results also showed that MyoD and MyoG were elevated at protein level in FGF21 overexpression cells (Figure 2(c)). Further, P53, a cell cycle inhibiting gene, was increased, while cell cycle genes Cyclin D3 and CDK4 were decreased in response to elevated FGF21 (Figure 2(c)). In addition, mRNA levels of cell cycle exit related genes, Rb, P21, P18, P19, P53, and P45, exhibited a significant increase; in contrast, the cell cycle genes, Cyclin D1, Cyclin D2, Cyclin E, CDK6, E2F1, and CDC20, were significantly decreased in FGF21 overexpression group (Figure 2(d)). Moreover, flow cytometry results showed that FGF21 overexpression significantly increased the percentage of cells in G1 phase whereas the percentage of cells in S phase was significantly decreased when compared with control (Figure 2(e)).

3.3. FGF21 Knockdown Attenuated Cell Cycle Exit Process

To further investigate the role of FGF21 in cell cycle exit, we performed FGF21 knockdown in C2C12 cells using siRNA. The mRNA expression levels of cell cycle exit genes Rb, P18, P21, P27, and P53 were all significantly decreased in FGF21 knockdown (Si-FGF21) group. The mRNA level of -Klotho showed no significant change after FGF21 knockdown (Figure 3(a)). In contrast to cell cycle exit genes, the mRNA levels of cell cycle genes were increased in response to FGF21 gene suppression (Figure 3(b)). Western blot results showed that the cell cycle genes Cyclin D1 and CDK4 were elevated, whereas the protein levels of cell cycle exit genes P21 and P53 were repressed in FGF21 knockdown group (Figure 3(c)).

4. Discussion

FGF21 is a pleiotropic secretion protein, which possesses multiple metabolic benefits including ameliorating insulin resistance, improving hepatic lipid accumulation, and extending lifespan [24, 4042]. In the past decades, the bulk of scientific research focused on the mechanism of FGF21 regulating glucose and lipid metabolism in obesity and diabetes. Lots of breakthroughs were made and FGF21 was considered as a drug candidate for some metabolic syndromes. In this study, we analyzed the effect of FGF21 on cell cycle progression and myogenic differentiation. Our results demonstrated that FGF21 downregulates the expression of cell cycle genes while it upregulates the expression of cell cycle inhibiting genes and myogenic genes, which was consistent with the point that, in response to myogenic differentiation, cell cycle exit genes were induced and cells were promoted to withdraw from cell cycle irreversibly [4345]. In addition, we found a probable pathway where FGF21 enhances myogenic differentiation through promoting cell cycle exit (Figure 4).

Myogenic differentiation is accompanied with increasing energy requirement and ATP level rise in the process of myoblasts differentiation into myotubes [46, 47]. In this study, the secretion of FGF21 is dramatically increased in response to myogenic differentiation. Also, FGF21 was reported to enhance glucose uptake in human skeletal muscle directly or via Glut1 and Glut4 [17, 48]. Further, FGF21 can promote mitochondrial function via upregulating the expression of PGC1α [34, 37]. Therefore, we deduce that elevated FGF21 plays crucial roles in energy generation to adjust increasing energy demand during myogenic differentiation.

It was suggested that FGF21 functions via combination to its receptor and β-Klotho complex [49, 50]. Skeletal muscle was not considered as an FGF21 signal target in the first few years due to the lack of β-Klotho expression [51]. However, more and more studies confirmed that FGF21 can be secreted from skeletal muscle and can target this tissue [31, 33, 52]. Moreover, it has been reported that β-Klotho can be induced in myotubes in humans [48, 53]. In addition, one study suggested that FGF21 signal transduction can be performed in a β-Klotho independent pathway [54]. In this study, the expression of β-Klotho was increased in response to myogenic differentiation but did not change significantly in FGF21 overexpression and knockdown cells. Thus, β-Klotho may not be regulated by FGF21 and FGF21 may function either in a β-Klotho dependent or a β-Klotho independent manner in skeletal muscle.

Our previous study indicated that FGF21 could induce myogenesis [33], while the molecular mechanisms remain obscure. It is well known that P21 is a main inhibitor of cell cycle progression, and P21 can be transcriptionally activated by P53 [55]. Also, Cyclin Ds/CDK4 and CDK6 and Cyclin E/CDK2 complexes function in G1 phase and G1/S transition [56, 57]. P21 not only inhibits Cyclin Ds/CDK4 and CDK6 complexes but also inhibits Cyclin Es/CDK2 complexes to arrest cell proliferation. Therefore, we proposed that FGF21 upregulates P53, elevated P53 transcriptionally activates P21, and P21 inhibits Cyclin/CDK complexes, which leads to G1 phase arrest and enhances myogenesis of myoblast cells.

In this study, we confirmed that, as expected, FGF21 is upregulated during myogenic differentiation of myoblasts. In addition, we showed that FGF21 could promote myogenic differentiation of myoblasts via enhancing cell cycle exit of myoblasts. Also, FGF21/P53/p21/Cyclin-CDK has been suggested as the key pathway for cell cycle exit mediated by FGF21 in C2C12. Taken together, our study provided new clue to better understand the roles of FGF21 in myogenesis.

Abbreviations

FGF21:Fibroblast growth factor 21
MyoG:Myogenin
CDKs:Cyclin-dependent kinases
MAPK:Mitogen-activated protein kinase
PI3K:Phosphoinositide 3-kinase
UCP1:Uncoupling protein 1
PGC1α:Peroxisome proliferator-activated receptor gamma coactivator 1-alpha.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Xinyi Liu and Yongliang Wang designed the experiments. Xinyi Liu performed the experiments and wrote the manuscript. Xinyi Liu, Yongliang Wang, Shuhong Zhao, and Xinyun Li analyzed the data. Xinyi Liu, Yongliang Wang, Shuhong Zhao, and Xinyun Li revised the manuscript. All authors read and approved the manuscript.

Acknowledgments

The authors would like to thank all the members of the laboratory for their help. This work was supported by the National High Technology Research and Development Program of China (2013AA102502), the National Natural Science Foundation of China (31361140365), and the grant from the National Major Special Projects of Science and Technology (2016ZX08006003-004).

Supplementary Materials

Supplement Table 1. Primers for quantitative PCR.

  1. Supplementary Material

References

  1. T. Nishimura, Y. Nakatake, M. Konishi, and N. Itoh, “Identification of a novel FGF, FGF-21, preferentially expressed in the liver,” Biochimica et Biophysica Acta: Gene Structure and Expression, vol. 1492, no. 1, pp. 203–206, 2000. View at: Publisher Site | Google Scholar
  2. A. Kharitonenkov, T. L. Shiyanova, A. Koester et al., “FGF-21 as a novel metabolic regulator,” Journal of Clinical Investigation, vol. 115, no. 6, pp. 1627–1635, 2005. View at: Publisher Site | Google Scholar
  3. N. Itoh and D. M. Ornitz, “Evolution of the Fgf and Fgfr gene families,” Trends in Genetics, vol. 20, no. 11, pp. 563–569, 2004. View at: Publisher Site | Google Scholar
  4. Y. Ogawa, H. Kurosu, M. Yamamoto et al., “BetaKlotho is required for metabolic activity of fibroblast growth factor 21,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7432–7437, 2007. View at: Google Scholar
  5. X. Ding, J. Boney-Montoya, B. M. Owen et al., “βKslotho is required for fibroblast growth factor 21 effects on growth and metabolism,” Cell Metabolism, vol. 16, no. 3, pp. 387–393, 2012. View at: Publisher Site | Google Scholar
  6. A. C. Adams, C. Yang, T. Coskun et al., “The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue,” Molecular Metabolism, vol. 2, no. 1, pp. 31–37, 2013. View at: Publisher Site | Google Scholar
  7. M. Ye, W. Lu, X. Wang et al., “FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function, and ER stress in obesity,” Endocrinology, vol. 157, no. 12, pp. 4754–4769, 2016. View at: Publisher Site | Google Scholar
  8. E. S. Muise, B. Azzolina, D. W. Kuo et al., “Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states,” Molecular Pharmacology, vol. 74, no. 2, pp. 403–412, 2008. View at: Publisher Site | Google Scholar
  9. R. J. Samms, M. J. Fowler, S. Cooper et al., “Photoperiodic regulation of FGF21 production in the Siberian hamster,” Hormones and Behavior, vol. 66, no. 1, pp. 180–185, 2014. View at: Publisher Site | Google Scholar
  10. S. M. Solon-Biet, V. C. Cogger, T. Pulpitel et al., “Defining the Nutritional and Metabolic Context of FGF21 Using the Geometric Framework,” Cell Metabolism, vol. 24, no. 4, pp. 555–565, 2016. View at: Publisher Site | Google Scholar
  11. M. K. Brahma, R. C. Adam, N. M. Pollak et al., “Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis,” Journal of Lipid Research, vol. 55, no. 11, pp. 2229–2241, 2014. View at: Publisher Site | Google Scholar
  12. Y. Izumiya, H. A. Bina, N. Ouchi, Y. Akasaki, A. Kharitonenkov, and K. Walsh, “FGF21 is an Akt-regulated myokine,” FEBS Letters, vol. 582, no. 27, pp. 3805–3810, 2008. View at: Publisher Site | Google Scholar
  13. M. K. Badman, P. Pissios, A. R. Kennedy, G. Koukos, J. S. Flier, and E. Maratos-Flier, “Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states,” Cell Metabolism, vol. 5, no. 6, pp. 426–437, 2007. View at: Publisher Site | Google Scholar
  14. T. Lundåsen, M. C. Hunt, L.-M. Nilsson et al., “PPARα is a key regulator of hepatic FGF21,” Biochemical and Biophysical Research Communications, vol. 360, no. 2, pp. 437–440, 2007. View at: Publisher Site | Google Scholar
  15. E. Hondares, R. Iglesias, A. Giralt et al., “Thermogenic activation induces FGF21 expression and release in brown adipose tissue,” Journal of Biological Chemistry, vol. 286, no. 15, pp. 12983–12990, 2011. View at: Publisher Site | Google Scholar
  16. T. Bobbert, F. Schwarz, A. Fischer-Rosinsky et al., “Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians,” Diabetes Care, vol. 36, no. 1, pp. 145–149, 2013. View at: Publisher Site | Google Scholar
  17. F. L. Mashili, R. L. Austin, A. S. Deshmukh et al., “Direct effects of FGF21 on glucose uptake in human skeletal muscle: Implications for type 2 diabetes and obesity,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 3, pp. 286–297, 2011. View at: Publisher Site | Google Scholar
  18. J. M. Gallego-Escuredo, J. Gómez-Ambrosi, V. Catalan et al., “Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients,” International Journal of Obesity, vol. 39, no. 1, pp. 121–129, 2015. View at: Publisher Site | Google Scholar
  19. F. M. Fisher, P. C. Chui, P. J. Antonellis et al., “Obesity is a fibroblast growth factor 21 (FGF21)-resistant state,” Diabetes, vol. 59, no. 11, pp. 2781–2789, 2010. View at: Publisher Site | Google Scholar
  20. K. R. Markan, M. C. Naber, S. M. Small, L. Peltekian, R. L. Kessler, and M. J. Potthoff, “FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue,” Molecular Metabolism, vol. 6, no. 6, pp. 602–610, 2017. View at: Publisher Site | Google Scholar
  21. R. Kruse, S. G. Vienberg, B. F. Vind, B. Andersen, and K. Højlund, “Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes,” Diabetologia, vol. 60, no. 10, pp. 2042–2051, 2017. View at: Publisher Site | Google Scholar
  22. Y. Wang, X. Liu, L. Hou, W. Wu, S. Zhao, and Y. Xiong, “Fibroblast growth factor 21 suppresses adipogenesis in pig intramuscular fat cells,” International Journal of Molecular Sciences, vol. 17, no. 1, article no. 11, 2015. View at: Publisher Site | Google Scholar
  23. T. Coskun, H. A. Bina, M. A. Schneider et al., “Fibroblast growth factor 21 corrects obesity in mice,” Endocrinology, vol. 149, no. 12, pp. 6018–6027, 2008. View at: Publisher Site | Google Scholar
  24. J. Xu, D. J. Lloyd, C. Hale et al., “Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice,” Diabetes, vol. 58, no. 1, pp. 250–259, 2009. View at: Publisher Site | Google Scholar
  25. A. Kharitonenkov and R. DiMarchi, “Fibroblast growth factor 21 night watch: advances and uncertainties in the field,” Journal of Internal Medicine, vol. 281, no. 3, pp. 233–246, 2017. View at: Publisher Site | Google Scholar
  26. A. Planavila, I. Redondo, E. Hondares et al., “Fibroblast growth factor 21 protects against cardiac hypertrophy in mice,” Nature Communications, vol. 4, article 2019, 2013. View at: Publisher Site | Google Scholar
  27. C. Zhang, Z. Huang, J. Gu et al., “Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway,” Diabetologia, vol. 58, no. 8, pp. 1937–1948, 2015. View at: Publisher Site | Google Scholar
  28. D. Cuevas-Ramos, P. Almeda-Valdés, C. E. Meza-Arana et al., “Exercise increases serum fibroblast growth factor 21 (FGF21) levels,” PLoS ONE, vol. 7, no. 5, Article ID e38022, 2012. View at: Publisher Site | Google Scholar
  29. K. H. Kim, S. H. Kim, Y.-K. Min, H.-M. Yang, J.-B. Lee, and M.-S. Lee, “Acute exercise induces FGF21 expression in mice and in healthy humans,” PLoS ONE, vol. 8, no. 5, Article ID e63517, 2013. View at: Publisher Site | Google Scholar
  30. P. Hojman, M. Pedersen, A. R. Nielsen et al., “Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia,” Diabetes, vol. 58, no. 12, pp. 2797–2801, 2009. View at: Publisher Site | Google Scholar
  31. Y. Tanimura, W. Aoi, Y. Takanami et al., “Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation,” Physiological Reports, vol. 4, article e12828, no. 12, 2016. View at: Publisher Site | Google Scholar
  32. F. Ribas, J. Villarroya, H. Elayne, M. Giralt, and F. Villarroya, “FGF21 expression and release in muscle cells: Involvement of MyoD and regulation by mitochondria-driven signalling,” Biochemical Journal, vol. 463, no. 2, pp. 191–199, 2014. View at: Publisher Site | Google Scholar
  33. X. Liu, Y. Wang, L. Hou, Y. Xiong, and S. Zhao, “Fibroblast Growth Factor 21 (FGF21) Promotes Formation of Aerobic Myofibers via the FGF21-SIRT1-AMPK-PGC1α Pathway,” Journal of Cellular Physiology, vol. 232, no. 7, pp. 1893–1906, 2017. View at: Publisher Site | Google Scholar
  34. F. Li, Y. Li, Y. Duan, C.-A. A. Hu, Y. Tang, and Y. Yin, “Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue,” Cytokine and Growth Factor Reviews, vol. 33, pp. 73–82, 2017. View at: Publisher Site | Google Scholar
  35. S. Keipert, M. Ost, K. Johann et al., “Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine,” American Journal of Physiology - Endocrinology and Metabolism, vol. 306, no. 5, pp. E469–E482, 2014. View at: Publisher Site | Google Scholar
  36. M. M. Kwon, S. M. O'Dwyer, R. K. Baker, S. D. Covey, and T. J. Kieffer, “FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1,” Cell Reports, vol. 13, no. 8, pp. 1521–1527, 2015. View at: Publisher Site | Google Scholar
  37. K. Ji, J. Zheng, J. Lv et al., “Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1α pathway,” Free Radical Biology and Medicine, vol. 84, pp. 161–170, 2015. View at: Publisher Site | Google Scholar
  38. M. J. Potthoff, T. Inagaki, S. Satapati et al., “FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 26, pp. 10853–10858, 2009. View at: Publisher Site | Google Scholar
  39. B. Vandanmagsar, J. D. Warfel, S. E. Wicks et al., “Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle,” Cell Reports, vol. 15, no. 8, pp. 1686–1699, 2016. View at: Publisher Site | Google Scholar
  40. S. Casteras, A. Abdul-Wahed, M. Soty et al., “The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice,” Diabetologia, vol. 59, no. 12, pp. 2645–2653, 2016. View at: Publisher Site | Google Scholar
  41. A. R. Mendelsohn and J. W. Larrick, “Fibroblast growth factor-21 is a promising dietary restriction mimetic,” Rejuvenation Research, vol. 15, no. 6, pp. 624–628, 2012. View at: Publisher Site | Google Scholar
  42. A. Salminen, A. Kauppinen, and K. Kaarniranta, “FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process,” Journal of Molecular Medicine, vol. 95, no. 2, pp. 123–131, 2017. View at: Publisher Site | Google Scholar
  43. L. A. Buttitta and B. A. Edgar, “Mechanisms controlling cell cycle exit upon terminal differentiation,” Current Opinion in Cell Biology, vol. 19, no. 6, pp. 697–704, 2007. View at: Publisher Site | Google Scholar
  44. L. Jahn, J.-I. Sadoshima, and S. Izumo, “Cyclins and cyclin-dependent kinases are differentially regulated during terminal differentiation of C2C12 muscle cells,” Experimental Cell Research, vol. 212, no. 2, pp. 297–307, 1994. View at: Publisher Site | Google Scholar
  45. S. X. Skapek, J. Rhee, D. B. Spicer, and A. B. Lassar, “Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase,” Science, vol. 267, no. 5200, pp. 1022–1024, 1995. View at: Publisher Site | Google Scholar
  46. J. Sin, A. M. Andres, D. J. R. Taylo R et al., “Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts,” Autophagy, vol. 12, no. 2, pp. 369–380, 2016. View at: Publisher Site | Google Scholar
  47. E. Barbieri, M. Guescini, C. Calcabrini et al., “Creatine Prevents the Structural and Functional Damage to Mitochondria in Myogenic, Oxidatively Stressed C2C12 Cells and Restores Their Differentiation Capacity,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5152029, 12 pages, 2016. View at: Publisher Site | Google Scholar
  48. M. S. Lee, S.-E. Choi, E. S. Ha et al., “Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-κB,” Metabolism: Clinical and Experimental, vol. 61, no. 8, pp. 1142–1151, 2012. View at: Publisher Site | Google Scholar
  49. X. Ding, J. Boney-Montoya, B. Owen et al., “βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism,” Cell Metabolism, vol. 16, no. 3, pp. 387–393, 2012. View at: Publisher Site | Google Scholar
  50. K. F. Tacer, A. L. Bookout, X. Ding et al., “Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse,” Molecular Endocrinology, vol. 24, no. 10, pp. 2050–2064, 2010. View at: Publisher Site | Google Scholar
  51. M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka et al., “βKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c,” Molecular Endocrinology, vol. 22, no. 4, pp. 1006–1014, 2008. View at: Publisher Site | Google Scholar
  52. Y. Luo and W. L. McKeehan, “Stressed liver and muscle call on adipocytes with FGF21,” Frontiers in Endocrinology, vol. 4, Article ID Article 194, 2013. View at: Publisher Site | Google Scholar
  53. J. Y. Jeon, S.-E. Choi, E. S. Ha et al., “Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles,” Endocrine, vol. 53, no. 1, pp. 97–106, 2016. View at: Publisher Site | Google Scholar
  54. K.-I. Tomiyama, R. Maeda, I. Urakawa et al., “Relevant use of Klotho in FGF19 subfamily signaling system in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1666–1671, 2010. View at: Publisher Site | Google Scholar
  55. A. G. Georgakilas, O. A. Martin, and W. M. Bonner, “p21: A Two-Faced Genome Guardian,” Trends in Molecular Medicine, vol. 23, no. 4, pp. 310–319, 2017. View at: Publisher Site | Google Scholar
  56. P. Hydbring, M. Malumbres, and P. Sicinski, “Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases,” Nature Reviews Molecular Cell Biology, vol. 17, no. 5, pp. 280–292, 2016. View at: Publisher Site | Google Scholar
  57. A. Karimian, Y. Ahmadi, and B. Yousefi, “Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage,” DNA Repair, vol. 42, pp. 63–71, 2016. View at: Publisher Site | Google Scholar

Copyright © 2017 Xinyi Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views1624
Downloads455
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.